|
|
News Breaks | | | | December 11, 2012 | | 10:08 EDT |  | IMMU | Immunomedics provides update on subcutaneous injections of Veltuzumab
Immunomedics announced that subcutaneous administration of veltuzumab, as a single agent, demonstrated promising activity in patients with relapsed immune thrombocytopenia, even in more heavily treated patients with the chronic disease, and in patients with chronic lymphocytic leukemia. In a published study, veltuzumab reversed life threatening anemia and thrombocytopenia in a patient with systemic lupus erythematosus who was unresponsive to rituximab. In non-Hodgkin lymphoma patients who had received prior therapies, 4 once-weekly infusions of veltuzumab produced a complete response rate of 25% in a study of 84 patients, even at the low dose of 80 mg/m2 given intravenously. | |
|
News For IMMU From The Last 14 Days Check below for free stories on IMMU the last two weeks. |
|
|
| May 8, 2013 | | 16:04 EDT |  | IMMU | Immunomedics reports Q3 EPS 11c , consensus (10c)
 Subscribe for More Information | | | May 7, 2013 | | 08:37 EDT | | IMMU | Immunomedics announces three new patent awards
Subscribe for More Information | |
|
|
|
|
|
|
